Q-omics provides the consensus-scored EPSTI1 profile across patient tissues and cancer cell-line models. EPSTI1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, EPSTI1 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, EPSTI1 protein abundance shows 16,588 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, HNSC, and LSCC as cancer lineages where EPSTI1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EPSTI1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EPSTI1 survival associations across molecular data types. EPSTI1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EPSTI1 RNA expression–survival associations across cancer types. High EPSTI1 expression shows unfavorable associations in UVM, PAAD, LGG and THYM, but favorable associations in SKCM and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for EPSTI1 RNA expression.
This table summarizes EPSTI1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for EPSTI1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EPSTI1 shows lower tumor expression in KICH and higher tumor expression in HNSC, KIRC, BLCA, STAD and COAD. The HNSC box plot shows higher EPSTI1 RNA expression in tumor versus normal tissue (log2 FC = +3.274, t-test p < 0.001).
This table shows molecular features associated with EPSTI1 in patient tissues and cancer cell lines. In patient samples, EPSTI1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, EPSTI1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
